tbuckley/cabot-search huggingface dataset:
The Frequency of Cytomegalovirus (CMV)-Specific CD8+ T Cells Distinguishes CMV Clinical Outcomes Following Hematopoietic Allogeneic Stem Cell Transplant: A Prospective Multicentre Cohort Study
Authors: Michelle K Yong, Monica Slavin, David S. Ritchie, Andrew Spencer, Paul U Cameron, Orla Morrissey, Allen Cheng, Assia Samri, Guislaine Carcelain, Brigitte Autran, Sharon R Lewin
Journal: Blood (2015)
Outpatient Management of Both Myeloablative and Reduced-Intensity Allogeneic HCT Results in Low Non-Relapse Mortality Irrespective of HCT-CI.
Authors: Asad Bashey, Karen Manion, Lawrence E. Morris, Kent Holland, Gerard Conaghan, Rebekkah Matthews, Amy Dooley, Connie Sizemore, Leslie Kerns, Scott R. Solomon
Journal: Blood (2007)
SAT0348 Asymptomatic Deep Vein Thrombosis in Anca-Associated Vasculitides
Authors: E. Makarov, S. Moiseev, P. Novikov
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Chronic inflammatory diseases, e.g. ANCA-associated vasculitides (AAV), are associated with increased incidence of venous thromboembolism (VTE) that can be asymptomatic in a proportion of patients. <h3>Objectives</h3> To evaluate a prevalence of asymptomatic deep vein thrombosis (DVT) in a cohort of AAV patients compared with healthy controls. <h3>Methods</h3> We used compression US to study the occurrence of asymptomatic DVT in 99 patients with AAV (67 females and 32 males, average age of 54.0 years, range of 18 to 77), including granulomatosis with polyangiitis (GPA; n=72), microscopic polyangiitis (MPA; n=13) and eosinophilic granulomatosis with polyangiitis (EGPA; n=14), and 514 healthy controls (339 females and 175 males; average age of 54.7 years, range of 17 to 89 years) without signs and symptoms of DVT. Signs of activity of AAV were present in 64 patients. <h3>Results</h3> Asymptomatic DVT was detected in 8 (8.1%) of 99 patients with AAV, including 3/72 (4.2%) GPA patients, 3/13 (23.1%) MPA patients and 2/14 (14.3%) EGPA patients. All 8 patients with DVT had active vasculitis. In 6 of 8 patients AAV was diagnosed within 6 months prior to US. A prevalence of traditional VTE risk factors was comparable in patients with and without DVT, but prednisolone dose at the time of US was higher in patients with DVT (38.8 vs 10.8 mg daily, p&lt;0.001). One patient with asymptomatic DVT died within 3 months after US from acute myocardial infarction, and one patient developed postthrombotic syndrome. There were no cases of pulmonary embolism. AAV was associated with significantly increased risk of asymptomatic DVT compared with healthy controls (OR =22.5, CI 4.7 to 107.7). This risk was even higher in patients with active AAV (OR =36.6, CI 7.6 to 174.5). <h3>Conclusions</h3> Patients with AAV have a high risk of asymptomatic DVT within 6 months after diagnosis. These data may justify wider screening for DVT in AAV. <h3>Disclosure of Interest</h3> None declared
Combined Chemotherapy (daunorubicin + cytarabine) and Dasatinib as Salvage Therapy of Chronic Myeloid Leukemia (CML) in Myeloid Blast Crisis, a Pilot Study.
Authors: Emmanuelle Nicolas-Virelizier, Matthias Jacquet-Lagreze, Damien Waz, Delphine Rea, Valerie Coiteux, Thibaut Leguay, Laurence Legros, Bénédicte Deau, Mohamad Sobh, Stephane Morisset, Mauricette Michallet, Franck Emmanuel Nicolini
Journal: Blood (2009)
Safety, Tolerability, and Pharmacokinetic Assessment of CG53135 Administered Intravenously in Patients with Advanced (Stage 4) Cancer (Single Rising-Dose Tolerance).
Authors: Joe Stephenson, Sanjay Goel, Pankaj Bhargava, Saroj Vadhan-Raj, Vincent Annino, Thomas Hawthorne, Yuan-Di Halvorsen, William Hahne
Journal: Blood (2004)
PTU-054 Therapeutic Monitoring of TNF-Alpha Inhibitors in Crohn’s Disease; Impact of Nice 2016 Guidelines in a UK District General Hospital
Authors: E Harrison, H Padmanabhan, A Shah, A Murugananthan, H Steed, M Brookes
Journal: Gut (2016)

<h3>Introduction</h3> Therapeutic anti-TNFα monitoring enables optimisation of anti-TNFα therapy. Recently, NICE supported therapeutic monitoring of TNFα inhibitors in patients with Crohn’s disease who fail to respond. However, NICE found the evidence for routine monitoring in patients responding adequately to be insufficient. Small studies show high Infliximab (INF) trough levels and low antibody levels to be associated with successful maintenance of remission. <h3>Methods</h3> A retrospective review of drug level monitoring in patients with Crohn’s disease taking anti-TNFα drugs was conducted. Patient demographics, IBD type, duration and distribution were recorded. Data were collected to compare against the NICE guidance (DG22). Trough levels, antibody presence and the use of concomitant immunosuppression (thiopurine and/or methotrexate) were noted. Any clinical impact of monitoring was recorded. <h3>Results</h3> Over 26 months monitoring was performed 93 times in 80 patients. 60% of all monitoring was clinically indicated in patients suspected to be non-responders. The remaining 40% were part of routine care. Of the 80 patients, 53% were male. Median age at first monitoring was 36 years (range 17–79). Median time from diagnosis of Crohn’s was 86 months (range 5–528). 26% had ileal, 30% had colonic and 44% had ileocolonic disease. 30% had stricturing and 8% had penetrating disease phenotypes. 39% had perianal disease. At diagnosis, 19% were aged 16 or below, 56% were aged 17 to 40 and 24% were aged over 40. Onset was unknown in 1%. For all drug monitoring, the median time from anti-TNFα initiation (59% INF; 41% Adalimumab (ADA)) was 60 weeks (range 6–470). 31% had concomitant immunosuppression. Antibodies were detected in 16% (22% INF; 8% ADA). Overall, as a result of monitoring, 49% continued their current anti-TNFα, 37% dose-escalated, 1% de-escalated, 8% stopped, 3% switched to ADA, 1% switched to INF and 1% changed to Vedulizumab. 13% started or increased thiopurine or methotrexate and 8% proceeded to surgery. Of those patients monitored as a part of routine care, 24% dose-escalated, 11% stopped anti-TNFα drugs and 5% switched to ADA. Doses were unchanged in 60%. <h3>Conclusion</h3> A large proportion of monitoring in our population was for the routine evaluation in patients on anti-TNFα drugs. These patients are now considered outside of NICE practice guidelines. Thus, adhering to NICE guidelines will lead to a substantial reduction in the number of our patients tested. However, in this group, the evaluation of drug levels influenced care in 40% of cases. Thus, further studies are needed to determine the benefits of routine drug level monitoring in stable patients on anti-TNFα drugs. <h3>Disclosure of Interest</h3> None Declared
Expression Profiles of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinases (TIMPs) in Myelodysplastic Syndromes (MDS): Level of MMP-9 Is Associated with Improved Prognosis in MDS Patients
Authors: Hui Yang, Carlos E. Bueso-Ramos, Sherry A. Pierce, Yue Wei, Zhihong Fang, Martin Nguyen, Michael Fernadez, Marylou Cardenas-Turanzas, Hagop M. Kantarjian, Guillermo Garcia-Manero
Journal: Blood (2012)
SAT0346 Cutaneous Vasculitis Associated To Connective Tissue Diseases and Other Autoimmune Disorders. Study of 35 Patients from A Single Centre
Authors: C. Fernández-Díaz, J. Loricera, R. Blanco, J.L. Hernández, V. Calvo-Río, F. Ortiz-Sanjuán, H. Fernández-Llaca, M.A. González-Lόpez, S. Armesto, C. González-Vela, M.Ά. González-Gay
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Cutaneous vasculitis (CV) can be a clinical manifestation of a connective tissue or other autoimmune disease. <h3>Objectives</h3> Our aim was to assess the frequency and clinical features of CV associated to connective tissue diseases. <h3>Methods</h3> Study of a large series of 766 unselected patients with CV attended in the same tertiary-care hospital. CV was considered as secondary to connective tissue disease or other autoimmune disorder when occurred in the setting of any of these conditions. <h3>Results</h3> In 35 (10 men/25 women; mean age±SD, 48±15 years) of 766 patients (4.57%) CV was associated to the following connective tissue disease or autoimmune disorder: systemic lupus erythematosus (SLE) (n=15), rheumatoid arthritis (n=9), Sjögren9s syndrome (n=5), ankylosing spondylitis (n=2), relapsing polychondritis (n=1), Behçet9s disease (n=1), sarcoidosis (n=1) and autoimmune hepatitis (n=1). All patients developed vasculitic skin lesions: palpable purpura (n=31), maculopapular erythema (n=4) and urticarial lesions (n=2). The most common CV locations were: lower limbs (n=30), upper limbs (n=12) and trunk (n=10). The mean duration of skin lesions was 13.83±7.62 days. Other clinical features were nephropathy (n=9), joint involvement (n=6), constitutional symptoms (n=4) and gastrointestinal involvement (n=1). Regarding laboratory parameters, elevated ESR was observed in 25 patients, hematuria in 4, anemia in 7 and proteinuria in 5 patients. Immunologic findings were as follows: positive rheumatoid factor (10 of 13 patients tested), positive antinuclear antibodies (15 of 19 patients tested), and decreased serum complement levels (11 of 20 patients tested). Twenty-five patients required some drug for CV: corticosteroids (n=22), cyclophosphamide (n=6), methotrexate (n=5), NSAIDs (n=4), azathioprine (n=4), chloroquine (n=3), hidroxichloroquine (n=2), dapsone (n=1) and rituximab (n=2). <h3>Conclusions</h3> CV, although infrequent, is not exceptional in the setting of any connective tissue disease or autoimmune disorder. <h3>Acknowledgement</h3> This study was supported by a grant from "Fondo de Investigaciones Sanitarias" PI12/00193 (Spain). This work was also partially supported by RETICS Programs, RD08/0075 (RIER) and RD12/0009/0013 from "Instituto de Salud Carlos III" (ISCIII) (Spain). <h3>Disclosure of Interest</h3> None declared
FRI0223 The Best Selection of Second Biologics for Patients with Rheumatoid Arthritis in Daily Clinical Practice
Authors: K. Saito, K. Nakano, S. Nakayamada, S. Kubo, I. Miyagawa, S. Hirata, Y. Tanaka
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Since the approval of infliximab (IFX) in 2003, 8 biologics have been approved for rheumatoid arthritis (RA) in Japan. However, little is known regarding what to do when patients have an inadequate response to first biologics in daily clinical practice. <h3>Objectives</h3> This study aimed to evaluate the effectiveness of biologics as 2nd-line use in RA patients in daily clinical practice from our university cohort (FIRST registry). <h3>Methods</h3> We retrospectively examined 2553 patients who were treated with biologics in our institute between July 2003 and December 2015. We compared the effectiveness of TNF-inhibitors (TNFi), TCZ, ABA as 2nd-line use and efficacy of switching from 1st TNFi to 2nd TNFi, TCZ or ABA based on retention rates and change in disease activity such as CDAI at 1 year, ΔCDAI (0–52W), ΔDAS28-ESR (LOCF). Propensity score (PS) were generated using multinomial logistic regression and the study groups were matched regarding baseline variables including age, disease duration, disease activity, concomitant use of MTX and PSL. In addition, in order to find out the characteristic of 2nd biologics, we conducted comparison between the upper (1yCDAI-H; low response) and lower (1yCDAI-L; good response) quartiles in CDAI at 1 y after switching. <h3>Results</h3> In terms of switching of biologics, better treatment outcome of ΔCDAI was observed in order of TCZ (n=141) &gt;2nd TNFi (n=186) &gt;ABT (n=91) but was comparable after the adjustment by PS. Comparison between the upper (1yCDAI-H) and lower (1yCDAI-L) quartiles in CDAI at 1 y after switching revealed that disease activity might improve despite of a high disease activity at switching in the case of TCZ as shown in Figure. In addition, high CRP and MMP-3 at switching were higher in the 1y CDAI-L group only in the case of switching to TCZ. <h3>Conclusions</h3> After adjustment using PS-score, RA patients with prior anti-TNF exposures had similar outcomes if they switched to a new TNFi as compared with initiation of TCZ or ABA. Also our results imply us that TCZ might bring about good outcome despite of disease activity at switching. Furthermore, higher CRP or MMP-3, suggesting inadequate suppression of IL-6 by first biologics, might predict better outcome of TCZ. <h3>Disclosure of Interest</h3> K. Saito: None declared, K. Nakano: None declared, S. Nakayamada: None declared, S. Kubo: None declared, I. Miyagawa: None declared, S. Hirata Speakers bureau: AbbVie, Eisai, Bristol Meyers Squibb, Y. Tanaka Grant/research support from: Mitsubishi-Tanabe, Chugai, MSD, Speakers bureau: Abbvie, Chugai, Astellas, Takeda, Santen, Mitsubishi-Tanabe, Pfizer, Janssen,
PTU-136 Heterogeneity in High Resolution Manometry (HRM) and Ambulatory PH Testing around The World in 2015: Abstract PTU-136 Table 1
Authors: R Sweis, M Fox
Journal: Gut (2016)

<h3>Introduction</h3> Despite advances in HRM and pH monitoring there is wide variation in technique and technology while reporting is often subjective and open to interpretation. This study assesses current practice around the world. <h3>Methods</h3> Through an on-line platform (Qualtrics LLC), a survey was distributed to unselected oesophageal units through international NGM societies. Questions explored infrastructure, technology, analysis and reporting. Results are presented as % of the total or mean±SD. <h3>Results</h3> 91 of 102 responses from 29 countries were analysable.(Table) 43 High (HVC) and 48 Low Volume Centres (LVC) were defined as more and less than 500 referrals/year. HVC employ more staff than LVC (p = 0.02) with more clinicians (3.0±1.0 vs. 2.6±1.2;p = 0.05), physiologists (1.6±1.1 vs. 2.0±1.3;p = 0.07) and nurses (3.3±1.2 vs. 2.4±1.1;p &lt; 0.001). Most units (63/91;69%) stop medication. 18 (20%) use &lt;12 sensor manometry, 75 (82%) &gt;26 sensor HRM and 53 (58%) use HRM-Impedance (some had several systems). Adjunctive testing is increasingly incorporated.(Table) To define pathology, Chicago Classification is used in 65 (71%) units. 60% comment on the upper sphincter. In the presence of a hiatus hernia analysis of oesophago-gastric junction morphology varies widely (p=NS). 64% proceed with pH-monitoring despite ≥Grade B oesophagitis. If intolerant of the catheter, 45% refer for catheter-free monitoring and 16.5% for barium; 14% do nothing further. HVC are more likely to employ catheter-free systems than LVC (47% vs. 17%;p &lt; 0.001). Of 86 (95%) units with Impedance-pH (Imp-pH), studies are performed on acid suppression in 54% with oesophagitis/Barrett’s. Overall, 8% perform all Imp-pH studies on therapy, 9% never do. Dietary modification (acid avoidance) is always recommended in 48%. Meals/snacks are not analysed in 91% units with standard pH and 84% with Imp-pH. Overall 17% do not exclude meals with either. 75% manually analyse every Imp-reflux event while 59% only target symptoms. For symptom-association, 30% units pool symptoms while 74% analyse each separately. Therapy advice is included in 49% HVC and 31% LVC (p = 0.044); 40% overall. <h3>Conclusion</h3> There is marked heterogeneity in methodology, interpretation and presentation of HRM and pH studies around the world. This survey sets the background from which agreement of standard operating procedures can begin. <h3>Disclosure of Interest</h3> R. Sweis Conflict with: Symposium funded by Given Img, M. Fox: None Declared
Immune Suppression by Placenta Derived Adherent Cells (PDAC) Correlate with Monocyte Chemoattractant Protein-1 and IL-2 Secretion.
Authors: Casper Paludan, Ryhor Harbacheuski, Rose Ann Murray, Megan Mendillo, Jorge Soler, Jia-Lun Wang, Qian Ye, James Edinger, Wolfgang Hofgartner, Gilla Kaplan, Robert Hariri
Journal: Blood (2006)
Caveolin-1 Is Required for VEGF- Triggered Multiple Myeloma Cell Migration and Is Targeted by Bortezomib (Velcade®).
Authors: Klaus Podar, Reshma Shringarpure, Yu-Tzu Tai, Melissa Simoncini, Martin Sattler, Kenji Ishitsuka, Paul G. Richardson, Teru Hideshima, Dharminder Chauhan, Anderson C. Kenneth
Journal: Blood (2004)
Bendamustine and Rituximab Combination In Untreated Indolent Non Follicular B-Cell Non-Hodgkin's Lymphomas. A Phase II Study From The Fondazione Italiana Linfomi (INFL09)
Authors: Stefano Luminari, Maria Cecilia Goldaniga, Marina Cesaretti, Lorella Orsucci, Alessandra Tucci, Alessandro Pulsoni, Flavia Salvi, Angelo Michele Carella, Alessandra Tedeschi, Antonio Pinto, Caterina Stelitano, Daniele Vallisa, Fiorella Ilariucci, Michele Spina, Luca Arcaini, Luigi Marcheselli, Massimo Federico, Luca Baldini
Journal: Blood (2013)
AB0457 How Much Different Is Juvenile Onset Systemic Lupus Erhytematosus? Data from A Romanian Cohort
Authors: I. Saulescu, T. Gudu, D. Opris, L. Groseanu, A. Borangiu, S. Daia-Iliescu, C. Constantinescu, R. Ionescu
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Systemic Lupus Erhytematosus (SLE) is a multiorgan disease in which pattern of evolution is linked to activity and damage. When the disease starts at an early age, all the outcomes might be influenced by this. <h3>Objectives</h3> The main focus of this study is to describe the differences between juvenile and adult onset SLE in a Romanian cohort. <h3>Methods</h3> 101 SLE patients were evaluated between March 2015 and December 2015. Patients were diagnosed with SLE according to ACR classification criteria and splited in 2 groups, taking into account age at disease onset: before and after 18. All patients agree to participate in this study. Data about demographic, clinical or serological characteristics, activity (SLEDAI) or damage (SLICC damage index SDI), treatment were collected. Statistical analisys was performed with SPSS 20.0. <h3>Results</h3> Our cohort was made from 18 patients with juvenile onset SLE and 83 with adult onset SLE. Mean age at diagnosis was 14.05 versus 37.89. The juvenile onset SLE group had significant more autoimmune disease as family background, mainly SLE and rheumatoid arthritis (33.3% versus 12.04%, p 0.025), significant more severe organ involvement during the disease evolution: SLE related neurologic involvement 33.3% versus 12% (p 0.025) and renal involvement 50% versus 16.8% (p 0.023), more frequent anti dsDNA Ab positives 88.8% versus 60.24% (p 0.021). This more severe pattern of evolution is also reflected by immunosuppressant therapy, Cyclophosphamide being used in juvenile subgroup in 66% cases versus 35.3% in adults (p 0.014). Interesting, there were no differences between cumulative damage between groups, as measured by SDI (p 0.24), with the mention that in juvenile onset patients, SDI&gt;1 was more frequent SLE related. This is in line with the fact that side effects of the corthicotherapie were identified more in adult onset SLE 61.44% versus 33.3% in juvenile onset (p 0.029). <h3>Conclusions</h3> Our data clearly show that juvenile onset SLE has more genetic background and it is more prone to a severe disease, renal and neurologic involvement being more frequent than in adult onset form. Severity seems to be related both to the activity, but also to fast damage accrual over time. Controlling the disease activity must be our goal, since cumulative irreversible damage is mainly SLE related for our patients. <h3>References</h3> Watson, L., Leone, V., Pilkington, C., et all, on behalf of the UK Juvenile-Onset Systemic Lupus Erythematosus Study Group, "Disease activity, severity, and damage in the UK juvenile-onset systemic lupus erythematosus cohort". Arthritis &amp; Rheumatism, 2012, 64: 2356–2365. doi: 10.1002/art.34410. <h3>Disclosure of Interest</h3> None declared
Subcutaneous Alemtuzumab (MabCampath) in Fludarabine-Refractory CLL (CLL2H Trial of the GCLLSG).
Authors: Stephan Stilgenbauer, Dirk Winkler, Andreas Bühler, Thorsten Zenz, Silja Groner, Raymonde Busch, Manfred Hensel, Ulrich Dührsen, Jürgen Finke, Peter Dreger, Ulrich Jäger, Eva Lengfelder, Lorenz Trümper, Ulrike Söling, Rudolf Schlag, Michael Hallek, Hartmut Döhner
Journal: Blood (2007)
Mesenchymal Stem Cell Magnetization: Magnetic Multilayer Microcapsule Uptake, Toxicity, Impact on Functional Properties, and Perspectives for Magnetic Delivery
Authors: Kirill V. Lepik, Albert R. Muslimov, Alexander S. Timin, Vladislav S. Sergeev, Dmitry S. Romanyuk, Ivan S. Moiseev, Elena V. Popova, Igor L. Radchenko, Alexander D. Vilesov, Oleg V. Galibin, Gleb B. Sukhorukov, Boris V. Afanasyev
Journal: Advanced Healthcare Materials (2016)

Mesenchymal stem cells (MSCs) are widely used in cell therapy due to their convenience, multiline differentiation potential, reproducible protocols, and biological properties. The potential of MSCs to impregnate magnetic microcapsules and their possible influence on cell function and ability to response to magnetic field have been explored. Interestingly, the cells suspended in media show much higher ability in internalization of microcapsules, then MSCs adhere into the surface. There is no significant effect of microcapsules on cell toxicity compared with other cell line-capsule internalization reported in literature. Due to internalization of magnetic capsules by the cells, such cell engineering platform is responsive to external magnetic field, which allows to manipulate MSC migration. Magnetically sorted MSCs are capable to differentiation as confirmed by their conversion to adipogenic and osteogenic cells using standard protocols. There is a minor effect of capsule internalization on cell adhesion, though MSCs are still able to form spheroid made by dozen of thousand MSCs. This work demonstrates the potential of use of microcapsule impregnated MSCs to carry internalized micron-sized vesicles and being navigated with external magnetic signaling.
Efficacy of Hematopoietic Stem Cell Transplantation from Alternative Donors in Pediatric Severe Aplastic Anemia: A Single-Center Experience
Authors: Jin Kyung Suh, Seong Wook Lee, Kyung-Nam Koh, Ho Joon Im, Eun Seok Choi, Seongsoo Jang, Jong Jin Seo
Journal: Blood (2014)
Differences In The Genome-Wide Epigenetic Signatures Of mRNA and Long Non-Coding RNA Genes In Mouse Erythroblasts and Megakaryocytes
Authors: Elisabeth F Heuston, Jens Lichtenberg, Stacie M Anderson, Vikram R Paralkar, Cheryl Keller Capone, Ross C Hardison, Mitchell J. Weiss, David M. Bodine
Journal: Blood (2013)
Selective Targeting of the JAK2V617F Mutation in Polycythemia Vera and Essential Thrombocythemia by ITF2357, a Novel Histone Deacetylase Inhibitor.
Authors: Vittoria Guerini, Valentina Barbui, Orietta Spinelli, Anna Salvi, Chiara Dellacasa, Martino Introna, Tiziano Barbui, Josée Golay, Alessandro Rambaldi
Journal: Blood (2007)
In Vitro and In Vivo Model of EBV-Positive Non-Hodgkin Plasmablastic Lymphoma with Focal Plasmacytic Differentiation
Authors: Ilaria Nichele, Alberto Zamò, Anna Bertolaso, Francesco Bifari, Martina Tinelli, Marta Franchini, Roberta Stradoni, Fiorenza Aprili, Giovanni Pizzolo, Mauro Krampera
Journal: Blood (2011)